Ubiquinol

Ubiquinol has been studied in 12 papers since 2012: 7 trials and 1 observational study in people, 2 in animals, 1 review; 4 in the past year. Its furthest trials in people are at phase 3. The newest paper, Sep 2, 2026: “Mitochondria-Targeted Nutraceuticals as Metabolic Adjuncts to Physical Rehabilitation in Older Adults with Sarcopenia or Frailty: A Narrative Review”.

InterventionPhase 3

12 papers study it39 more mention it27 findingsUpdated

PubChemChEBIMeSH

More supplements

See all 51 papers on ubiquinol

At a glance

The findings reach people, from one lab or study. 5 independent labs in 5 countries; 15 trials, 2 about aging, 3 with no results posted.

“90 days of ubiquinol (200 mg) supplementation resulted in plasma CoQ10 levels being four times that of the placebo group at study end (p < 0.001)”
Effect of Ubiquinol on Cognitive Function, Blood Pressure, Arterial Stiffness, and Biomarkers of Oxidative Stress and Inflammation in the Elderly: A Randomized TrialAntioxidants (Basel, Switzerland)2026doi:10.3390/antiox15070806

1 of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 5 independent labs in 5 countries
  • 1 finding against
  • 15 trials, 2 about aging, 3 with no results posted
  • Funders: Australian Government and 6 more
  • 2 of 15 trials sponsored by its developers
  • Human trial7
  • Humans1
  • Animals2

6 studies gave ubiquinol to people and measured what changed.

What changedDesignPeopleSource

up: Increases plasma CoQ10four times the placebo group

no change: Has no effect on cognitive function

no change: Has no effect on oxidative stress biomarkers

Randomized trial90 days111 people60 years and olderOlder adults; at study end versus placeboAntioxidants (Basel, Switzerland), Jun 27, 2026

no change: Has no effect on oxidized LDL

Randomized trial12 weeks20 people18–60 yearsThai adults with prediabetesBioMed research international, Mar 8, 2026

up: Improves flow-mediated dilation+1.28% ± 0.90% (200 mg/day), +1.34% ± 1.44% (100 mg/day) vs −0.41% ± 1.51% (placebo)

Randomized trial8 weeks51 peopleaged 35–65 yearsMen and post-menopausal women aged 35–65 yearsNutrients, Apr 15, 2020

no change: Has no effect on physical function

down: Prevents coenzyme Q10

down: Decreases reactive oxygen species–37.4% and –35.5%

Randomized trial1 month21 peoplemales26 ± 5Healthy trained malesRedox report : communications in free radical research, Dec 1, 2018

down: Decreases alanine aminotransferase

down: Decreases alkaline phosphatase

Randomized trial12 weeksWith simvastatinExperimental biology and medicine (Maywood, N.J.), Sep 30, 2015

What did studies of ubiquinol find?

19

Studies of ubiquinol measured 19 outcomes, among them oxidized LDL, oxidative stress and ROS signaling and flow-mediated dilation.

Oxidized LDL

no changein humans1downin humans1downin reviews1

1 study
  1. Ubiquinol showed no clear effect on oxidized LDL in humans.

    “At 12 weeks, the between‐group difference in oxLDL was not significant (p = 0.801).”

    Human trial12 weeksn = 20

    Effects of Ubiquinol on Oxidized Low-Density Lipoprotein in Prediabetic Patients: A Randomized, Double-Blinded, Placebo-Controlled Study

    BioMed research international

  2. Ubiquinol decreases oxidized LDL in prediabetic patients (p = 0.049).

    “the ubiquinol group demonstrated a significant within-group reduction in plasma oxLDL compared with baseline (p = 0.049)”

    Human trialin prediabetic patientsplasma100 mg/day12 weeks

    Effects of Ubiquinol on Oxidized Low-Density Lipoprotein in Prediabetic Patients: A Randomized, Double-Blinded, Placebo-Controlled Study

    BioMed research international

  3. Ubiquinol decreases oxidized LDL.

    “However, the ubiquinol group exhibited a statistically significant within‐group reduction in mean oxLDL from 53.16 ± 6.79 at baseline to 50.16 ± 8.77 after 12 weeks of daily ubiquinol supplement (p = 0.049).”

    Review12 weeksn = 10

    Effects of Ubiquinol on Oxidized Low-Density Lipoprotein in Prediabetic Patients: A Randomized, Double-Blinded, Placebo-Controlled Study

    BioMed research international

More on Oxidized LDL

Oxidative stress and ROS signaling

downin humans1

1 study
  1. Ubiquinol decreases oxidative stress and ROS signaling in humans.

    “A highly significant and dose-dependent decrease in the percentage of oxidized CoQ10 was observed both at 4 weeks (F = 11.023, p < 0.001) and at 8 weeks (F = 10.087; p < 0.001”

    Human trial8 weeksn = 51

    Ubiquinol Ameliorates Endothelial Dysfunction in Subjects with Mild-to-Moderate Dyslipidemia: A Randomized Clinical Trial

    Nutrients

  2. Ubiquinol decreases oxidative stress and ROS signaling in humans (moderate dyslipidemia) (p = 0.017).

    “while LDL oxidation lag time improved significantly in those receiving 200 mg/day (p = 0.017)”

    Human trialmoderate dyslipidemiaplasma200 mg/day8 weeksn = 48

    Ubiquinol Ameliorates Endothelial Dysfunction in Subjects with Mild-to-Moderate Dyslipidemia: A Randomized Clinical Trial

    Nutrients

More on Oxidative stress and ROS signaling

Flow-mediated dilation

upin humans1

1 study
  1. Ubiquinol improves flow-mediated dilation in humans (+1.28% ± 0.90% (200 mg/day), +1.34% ± 1.44% (100 mg/day) vs −0.41% ± 1.51% (placebo)).

    “According to repeated measures one-way ANOVA, at the end of the study (week 8), subjects in both treatment groups showed a significant FMD increase compared with those receiving the placebo (200 mg/day, +1.28% ± 0.90%; 100 mg/day, +1.34% ± 1.44%; placebo −0.41% ± 1.51%; F = 9.145; p < 0.001; ).”

    Human trial8 weeksn = 51

    Ubiquinol Ameliorates Endothelial Dysfunction in Subjects with Mild-to-Moderate Dyslipidemia: A Randomized Clinical Trial

    Nutrients

  2. Ubiquinol improves flow-mediated dilation in humans (moderate dyslipidemia) (200 mg/day, +1.28% ± 0.90%; 100 mg/day, +1.34% ± 1.44%; p < 0.001).

    “demonstrated a significantly increased FMD in both treated groups compared with the placebo group (200 mg/day, +1.28% ± 0.90%; 100 mg/day, +1.34% ± 1.44%; p < 0.001)”

    Human trialmoderate dyslipidemiabrachial artery100 or 200 mg/day8 weeksn = 48

    Ubiquinol Ameliorates Endothelial Dysfunction in Subjects with Mild-to-Moderate Dyslipidemia: A Randomized Clinical Trial

    Nutrients

Reactive oxygen species

downin humans1

1 study
  1. Ubiquinol decreases reactive oxygen species in humans (–37.4% and –35.5%).

    “However, in the recovery phase, a distinct ROS scavenging effect was evident: a highly significant decrease in intracellular ROS was observed in the ubiquinol treated group at 90 and 150 min (–37.4% and –35.5%; p <.01).”

    Human trialPBMCs1 monthmalesn = 21

    Effect of ubiquinol supplementation on biochemical and oxidative stress indexes after intense exercise in young athletes

    Redox report : communications in free radical research

  2. Ubiquinol decreases reactive oxygen species in humans after a single bout of intense exercise.

    “ubiquinol supplementation was associated with a significant decrease in cytosolic ROS”

    Human trialafter a single bout of intense exercisesupplementationperipheral blood mononuclear cells200 mg/day1 monthmalesn = 21

    Effect of ubiquinol supplementation on biochemical and oxidative stress indexes after intense exercise in young athletes

    Redox report : communications in free radical research

More on Reactive oxygen species

Aspartate aminotransferase

no changein humans1

1 study
  1. Ubiquinol showed no clear effect on aspartate aminotransferase.

    “In contrast, we found no alteration of AST activity in response to Q10H2 supplementation.”

    Human trial14 daysmalesn = 53

    Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans

    BMC research notes

  2. Ubiquinol showed no clear effect on aspartate aminotransferase in humans (cohort II).

    “Of note, other liver enzymes (i.e., aspartate aminotransferase, AST) were not affected by Q10H2 supplementation.”

    Human trialcohort II150 mg/d14-daymalesn = 53

    Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans

    BMC research notes

More on Aspartate aminotransferase

GGT1

downin humans1

1 study
  1. Ubiquinol decreases GGT1 (fold change of -1.49).

    “Indeed, we found that Q10H2 supplementation reduced the GGT1 mRNA level with a fold change of -1.49 and the GOT2 mRNA level with a fold change of -1.34.”

    Human trial14 daysn = 3

    Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans

    BMC research notes

  2. Ubiquinol decreases GGT1 in humans (cohort II) (1.49-fold).

    “GGT1 mRNA levels declined 1.49-fold after Q10H2 supplementation.”

    Human trialcohort II150 mg/d14-daymalesn = 53

    Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans

    BMC research notes

More on GGT1

Gamma-glutamyltransferase

downin humans1

1 study
  1. Ubiquinol decreases gamma-glutamyltransferase (20.49 ± 10.36 U/l to 17.79 ± 7.68 U/l).

    “Figure A shows a significant decrease of GGT activity from T0 to T14 (20.49 ± 10.36 U/l to 17.79 ± 7.68 U/l; p < 0.001).”

    Human trial14 daysmalesn = 53

    Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans

    BMC research notes

  2. Ubiquinol decreases gamma-glutamyltransferase in humans (cohort II) (p < 0.001).

    “Q10H2 supplementation (cohort II) caused a significant decrease in serum GGT activity from T0 to T14 (p < 0.001).”

    Human trialcohort IIsupplementationserum150 mg/d14-daymalesn = 53

    Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans

    BMC research notes

More on Gamma-glutamyltransferase

Inflammation biomarkers

no changein humans1

1 study
  1. Ubiquinol showed no clear effect on inflammation biomarkers in humans (at study end, adjusted for baseline values and demographics).

    “ubiquinol supplementation did not facilitate group differences (controlling for baseline values and relevant demographics) in cognitive function, blood biomarkers reflective of oxidative stress or inflammation”

    Human trialat study end, adjusted for baseline values and demographics200 mg90 days

    Effect of Ubiquinol on Cognitive Function, Blood Pressure, Arterial Stiffness, and Biomarkers of Oxidative Stress and Inflammation in the Elderly: A Randomized Trial

    Antioxidants (Basel, Switzerland)

More on Inflammation biomarkers

Oxidative stress biomarkers

no changein humans1

1 study
  1. Ubiquinol showed no clear effect on oxidative stress biomarkers in humans (at study end, adjusted for baseline values and demographics).

    “ubiquinol supplementation did not facilitate group differences (controlling for baseline values and relevant demographics) in cognitive function, blood biomarkers reflective of oxidative stress or inflammation”

    Human trialat study end, adjusted for baseline values and demographics200 mg90 days

    Effect of Ubiquinol on Cognitive Function, Blood Pressure, Arterial Stiffness, and Biomarkers of Oxidative Stress and Inflammation in the Elderly: A Randomized Trial

    Antioxidants (Basel, Switzerland)

More on Oxidative stress biomarkers

Cognitive function

no changein humans1

1 study
  1. Ubiquinol showed no clear effect on cognitive function in humans (at study end, adjusted for baseline values and demographics).

    “ubiquinol supplementation did not facilitate group differences (controlling for baseline values and relevant demographics) in cognitive function, blood biomarkers reflective of oxidative stress or inflammation”

    Human trialat study end, adjusted for baseline values and demographics200 mg90 days

    Effect of Ubiquinol on Cognitive Function, Blood Pressure, Arterial Stiffness, and Biomarkers of Oxidative Stress and Inflammation in the Elderly: A Randomized Trial

    Antioxidants (Basel, Switzerland)

Plasma CoQ10

upin humans1

1 study
  1. Ubiquinol increases plasma CoQ10 in humans (at study end versus placebo) (four times the placebo group).

    “90 days of ubiquinol (200 mg) supplementation resulted in plasma CoQ10 levels being four times that of the placebo group at study end (p < 0.001)”

    Human trialat study end versus placebo200 mg90 days

    Effect of Ubiquinol on Cognitive Function, Blood Pressure, Arterial Stiffness, and Biomarkers of Oxidative Stress and Inflammation in the Elderly: A Randomized Trial

    Antioxidants (Basel, Switzerland)

More on Plasma CoQ10

Coenzyme Q10

downin humans1

1 study
  1. Ubiquinol prevents coenzyme Q10 in humans.

    “This increase efficiently counteracted CoQ10 deprivation induced by exercise.”

    Human trialplasma1 monthmalesn = 21

    Effect of ubiquinol supplementation on biochemical and oxidative stress indexes after intense exercise in young athletes

    Redox report : communications in free radical research

More on Coenzyme Q10

Physical function

no changein humans1

1 study
  1. Ubiquinol showed no clear effect on physical function in humans.

    “No significant differences were observed in terms of ability of ubiquinol to allow a prolonged run at higher speed.”

    Human trial1 monthmalesn = 21

    Effect of ubiquinol supplementation on biochemical and oxidative stress indexes after intense exercise in young athletes

    Redox report : communications in free radical research

Alkaline phosphatase

downin humans1

1 study
  1. Ubiquinol decreases alkaline phosphatase in humans with simvastatin.

    “In ubiquinol supplementation group, alanine aminotransferase and alkaline phosphatase were significantly down-regulated after 12 weeks”

    Human trialwith simvastatin12 weeks

    MicroRNAs as biomarkers of hepatotoxicity in a randomized placebo-controlled study of simvastatin and ubiquinol supplementation

    Experimental biology and medicine (Maywood, N.J.)

More on Alkaline phosphatase

Alanine aminotransferase

downin humans1

1 study
  1. Ubiquinol decreases alanine aminotransferase in humans with simvastatin.

    “In ubiquinol supplementation group, alanine aminotransferase and alkaline phosphatase were significantly down-regulated after 12 weeks”

    Human trialwith simvastatin12 weeks

    MicroRNAs as biomarkers of hepatotoxicity in a randomized placebo-controlled study of simvastatin and ubiquinol supplementation

    Experimental biology and medicine (Maywood, N.J.)

More on Alanine aminotransferase

All 19

Has ubiquinol been tested in people?

2 of 15 about aging

Yes: 7 trials and 1 observational study in people have been published, and 14 trials are registered.

Every condition in trials

All 19

Trial sponsors

Latest

Dec 2025: 1Jan 2026: 1Feb 2026: 0Mar 2026: 2Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 1Aug 2026: 0Sep 2026: 2Oct 2026: 0Nov 2026: 08 papers in 12 months

See all 51 papers on ubiquinol